4//SEC Filing
SGX PHARMACEUTICALS, INC. 4
Accession 0001233840-08-000009
CIK 0001125603operating
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 4:21 PM ET
Size
17.2 KB
Accession
0001233840-08-000009
Insider Transaction Report
Form 4
BIOTECHNOLOGY VALUE FUND L P
10% OwnerOther
Transactions
- Purchase
Common Stock
2008-06-18$1.45/sh+644,000$933,800→ 4,209,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+187,000$271,150→ 3,565,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+274,257$397,673→ 3,378,574 total(indirect: See footnotes)
BVF PARTNERS L P/IL
10% OwnerOther
Transactions
- Purchase
Common Stock
2008-06-18$1.45/sh+274,257$397,673→ 3,378,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+187,000$271,150→ 3,565,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+644,000$933,800→ 4,209,574 total(indirect: See footnotes)
BIOTECHNOLOGY VALUE FUND II LP
10% OwnerOther
Transactions
- Purchase
Common Stock
2008-06-18$1.45/sh+274,257$397,673→ 3,378,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+644,000$933,800→ 4,209,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+187,000$271,150→ 3,565,574 total(indirect: See footnotes)
BVF INC/IL
10% OwnerOther
Transactions
- Purchase
Common Stock
2008-06-18$1.45/sh+187,000$271,150→ 3,565,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+644,000$933,800→ 4,209,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+274,257$397,673→ 3,378,574 total(indirect: See footnotes)
BVF INVESTMENTS LLC
10% OwnerOther
Transactions
- Purchase
Common Stock
2008-06-18$1.45/sh+274,257$397,673→ 3,378,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+187,000$271,150→ 3,565,574 total(indirect: See footnotes) - Purchase
Common Stock
2008-06-18$1.45/sh+644,000$933,800→ 4,209,574 total(indirect: See footnotes)
Footnotes (6)
- [F1]The shares reported in this response are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"). Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments.
- [F2]Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.
- [F3]Shares directly beneficially owned by BVF, L.P.
- [F4]Shares directly beneficially owned by BVF2, L.P.
- [F5]Shares directly beneficially owned by Investments.
- [F6]Total amount of shares indirectly beneficially owned by Partners and BVF Inc.
Documents
Issuer
SGX PHARMACEUTICALS, INC.
CIK 0001125603
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001125603
Filing Metadata
- Form type
- 4
- Filed
- Jun 19, 8:00 PM ET
- Accepted
- Jun 20, 4:21 PM ET
- Size
- 17.2 KB